Cellectis (NASDAQ:CLLS) Rating Increased to Buy at StockNews.com

StockNews.com upgraded shares of Cellectis (NASDAQ:CLLS) from a hold rating to a buy rating in a report released on Friday morning.

Cellectis Stock Up 1.3 %

Shares of CLLS stock opened at $1.53 on Friday. Cellectis has a twelve month low of $1.10 and a twelve month high of $3.38. The stock has a market cap of $85.04 million, a P/E ratio of -1.18 and a beta of 3.22. The stock has a 50 day moving average of $1.33 and a 200 day moving average of $1.62. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.48.

Cellectis (NASDAQ:CLLS) last posted its earnings results on Thursday, March 13th. The biotechnology company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of $0.06 by ($0.22). Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. The firm had revenue of $33.22 million for the quarter, compared to analysts’ expectations of $5.90 million. As a group, sell-side analysts expect that Cellectis will post -0.46 EPS for the current year.

Institutional Investors Weigh In On Cellectis

Several hedge funds have recently modified their holdings of CLLS. Wells Fargo & Company MN increased its stake in shares of Cellectis by 103.4% in the 4th quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 12,500 shares in the last quarter. Millennium Management LLC acquired a new stake in Cellectis in the fourth quarter valued at approximately $962,000. Finally, B Group Inc. purchased a new stake in shares of Cellectis in the fourth quarter valued at approximately $5,547,000. 63.90% of the stock is owned by hedge funds and other institutional investors.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.